Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6280959 | NOVARTIS | Metal complexes |
Oct, 2018
(5 years ago) | |
US7473686 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
US7452874 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(1 year, 5 months ago) | |
US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(1 year, 2 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6280959 (Pediatric) | NOVARTIS | Metal complexes |
Apr, 2019
(5 years ago) | |
US7790704 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
US7332481 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
US7790704 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
US7332481 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
US7452874 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
US7473686 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(11 months ago) | |
US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(11 months ago) | |
US7795293 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(5 months ago) | |
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(1 year, 8 months from now) | |
US8062665 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
US8052993 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
US8071129 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
US8828430 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
US8052995 | NOVARTIS | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
US8052994 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
US8062665 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
US8828430 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
US8052993 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
US8052994 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
US8071129 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
US8052995 (Pediatric) | NOVARTIS | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) |
Promacta is owned by Novartis.
Promacta contains Eltrombopag Olamine.
Promacta has a total of 28 drug patents out of which 14 drug patents have expired.
Expired drug patents of Promacta are:
Promacta was authorised for market use on 20 October, 2011.
Promacta is available in tablet;oral dosage forms.
Promacta can be used as patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy, treatment of idiopathic thrombocytopenic purpura (itp), combination with immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia, treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp), treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp), treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy.
Drug patent challenges can be filed against Promacta from 26 February, 2021.
The generics of Promacta are possible to be released after 01 February, 2028.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-210) | Nov 16, 2025 |
New Indication(I-711) | Jun 11, 2018 |
New Dosing Schedule(D-149) | Jun 11, 2018 |
Pediatric Exclusivity(PED) | Feb 26, 2022 |
Orphan Drug Exclusivity(ODE-75) | Aug 26, 2021 |
New Indication(I-664) | Nov 16, 2015 |
New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
Orphan Drug Exclusivity(ODE) | Nov 20, 2015 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
NCE-1 date: 26 February, 2021
Market Authorisation Date: 20 October, 2011
Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Patients with severe aplastic anemia who have had an insufficien...
Dosage: TABLET;ORAL